Curavit Acquires Lindus Health Clinical Research Organization Assets to Expand US and European Trial Operations

Curavit Clinical Research has acquired the clinical research organization (CRO) assets of Lindus Health, expanding its operations into Europe and adding capabilities that the company says will allow life science sponsors to run multi-region studies under a single partner.¹

The transaction follows Lindus Health's decision to shift its focus to developing its own pipeline of therapeutic assets as Lindus Therapeutics.

The combined organization is designed to offer sponsors access to accelerated global site activation, remote patient recruitment, and decentralized and hybrid trial designs across pharma, biotech, medtech, diagnostics, and digital health.

Curavit also operates a Remote Clinical Site infrastructure alongside its standard CRO services, a combination the company says lowers trial costs, improves participant retention, and delivers clinical-grade data across both regions.

The integration addresses a gap the company identifies in the current CRO market: sponsors pursuing multi-country trials have historically had to choose between regional niche providers with limited geographic reach or large legacy CROs that move more slowly.

The combined Curavit operation is intended to offer a third option, pairing an agile operational model with a broader geographic footprint.

"We are pleased to partner with Curavit as the company enters its next phase of growth," said Nate Lentz, managing partner at Osage Venture Partners and Curavit board member, in a company press release. "Clinical research is evolving rapidly, and sponsors increasingly need more flexible, technology-enabled approaches to generating clinical evidence. Curavit brings together deep clinical expertise, innovative trial models, and differentiated patient recruitment capabilities to help sponsors run trials faster and more efficiently. We believe Curavit is exceptionally well positioned to become a leader in the next generation of clinical research."

"Sponsors no longer have to choose between regional niche CROs or large, traditional providers when launching multi-country trials," added Joel Morse, chief executive officer and co-founder of Curavit, in the press release. "By combining Lindus' European clinical assets and team with Curavit's proven US CRO, technology, and Remote Clinical Site infrastructure, we are offering sponsors a unified, alternative global solution. Life science sponsors can now recruit faster, reduce site burden, and run high-quality prospective trials across both North America and Europe under a single, agile operational partner."

A perspective from the Lindus side

The acquisition comes after Applied Clinical Trials featured Meri Beckwith, co-CEO of Lindus Health, in a video interview in August 2025, in which he discussed trial design discipline and organizational agility in the context of an increasingly unpredictable regulatory environment.²

Beckwith's argument was that breakthrough designation should not lead sponsors to treat trial design with any less rigor, and that the more important capability to cultivate is operational agility—the ability to generate additional data quickly if the FDA shifts its expectations.

"The best thing that sponsors can do in these times of uncertainty with the FDA is to cultivate agility," Beckwith said. "If the worst happens, and the FDA effectively moves the goal posts on you, and you need to generate more data, cultivate agility in your organization to be able to generate that data or even an entire new study, worst case at a reasonable cost."

He described a pattern across the industry of sponsors gold-plating studies through practices like 100% source data verification, extended follow-up periods, and large numbers of secondary and exploratory endpoints—an approach that makes trials lengthy and expensive without necessarily improving regulatory outcomes. His recommendation was for sponsors to pursue more shots on goal rather than concentrating resources on making any single study as comprehensive as possible.

The Lindus Health CRO assets now sit within Curavit's broader operational structure, while the Lindus Therapeutics entity moves forward as a separate organization with its own pipeline focus.

References

1. Curavit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science Sponsors. News release. Curavit. August 18, 2026. Accessed August 20, 2026. https://www.prnewswire.com/news-releases/curavit-expands-clinical-research-capabilities-with-acquisition-of-lindus-health-cro-assets-accelerating-global-trial-execution-for-life-science-sponsors-302854586.html?tc=eml_cleartime
2. Balancing Speed and Rigor in Accelerated Trial Pathways. Applied Clinical Trials. August 13, 2025. Accessed August 20, 2026. https://www.appliedclinicaltrialsonline.com/view/balancing-speed-rigor-accelerated-trial-pathways